This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Genta's Genasense Still a Long Shot

The phase III study enrolled 120 patients who were given a combination of Genasense plus chemotherapy; another 121 patients were given chemotherapy alone. All patients in the study were diagnosed with advanced CLL, which means they had received, and failed, prior therapies.

Nineteen patients, or 16%, in the Genasense arm of the study achieved a major response -- defined as a complete response or so-called nodular partial response, compared to with eight patients, or 7%, in the control arm. This result, the study's primary endpoint, was statistically significant, albeit not robustly so with a so-called p value of 0.039. [A p value of 0.05 is required for a study to reach statistical significance, but strong data typically have a p value of less than 0.01.]

But a more conventional primary endpoint in CLL studies looks at overall response rate, defined as a complete response, nodular partial responses and partial response. When the Genasense data were analyzed this way, overall response in the Genasense arm was 41%, less than the 45% overall response rate in the control arm.

Also, patients in the Genasense arm of the study progressed (their disease worsened) at a median time of 6.1 months, faster than the 8.9 months for patients in the control arm. Overall survival data were not analyzed, pending further maturing of the data.

Despite a series of setbacks this year that have left Genta reeling, the company seems intent to push ahead with Genasense's development. No doubt, persistence sometimes pays off. But for Genta, the second time will not likely be the charm.
Adam Feuerstein writes regularly for In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in He also doesn't invest in hedge funds or other private investment partnerships. He invites you to send your feedback to .
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.02 0.00%
FB $104.07 0.00%
GOOG $683.57 0.00%
TSLA $162.60 0.00%
YHOO $27.97 0.00%


Chart of I:DJI
DOW 16,204.97 -211.61 -1.29%
S&P 500 1,880.05 -35.40 -1.85%
NASDAQ 4,363.1440 -146.4150 -3.25%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs